Skip to content

Clinical trials

Observational Hypercholesterolemia trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hypercholesterolemia Phase: Observational Clear all

162 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20012
20021
20036
20046
20051
20064
20078
20085
20097
201012
20112
20129
20134
20143
20153
20168
20175
20184
20192
20208
20215
20228
20235
202415
20255
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed113
Unknown status17
Recruiting10
Active, not recruiting5
Not yet recruiting5
Terminated5
Withdrawn4
Enrolling by invitation2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca25
National Heart, Lung, and Blood Institute (NHLBI)18
Organon and Co9
Novartis Pharmaceuticals5
Amgen4
Federico II University4
JW Pharmaceutical4
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company3
Elpen Pharmaceutical Co. Inc.3
Gachon University Gil Medical Center3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hypercholesterolemia162
Cardiovascular Diseases37
Hypertension26
Heart Diseases23
Dyslipidemias21
Diabetes Mellitus20
Atherosclerosis17
Coronary Disease15
Hyperlipidemias11
Hyperlipoproteinemia Type II10

Trials

Showing 76 to 100 of 162. Each trial links to its page on Pharma Observatory.

62 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.